Frontier IP Group - Exscientia and SRI International collaborate
Portfolio news -
The collaboration will see the two companies implement a new approach to drug discovery by integrating SRI's fully automated synthetic-chemistry system with Exscientia's Centaur ChemistTM system.
Exscientia statement in full:
Companies will combine SynFini and Centaur Chemist platforms to focus on small-molecule oncology target
Exscientia, a clinical-stage Artificial Intelligence (AI) drug-discovery company and
Through the collaboration, the companies will combine SRI's fully automated SynFini™ synthetic-chemistry system with Exscientia's Centaur Chemist™ AI platform to expedite discovery of selective molecules for a high value oncology target.
"Both the SynFini and Centaur Chemist platforms have demonstrated ability to overcome key drug discovery challenges," said
SRI's end-to-end SynFini platform automates the design, reaction screening and optimization (RSO), and production of target molecules. It was developed to bring new drugs to the clinic more quickly and affordably by accelerating chemical discovery and development. The SynFini closed-loop system comprises three components that work seamlessly together: a software platform (SynRoute™), a reaction screening platform (SynJet™), and a multi-step flow chemistry automation and development platform (AutoSyn™).
Exscientia is the first company to successfully apply AI technologies to design small molecule compounds that have reached the clinic. Molecules generated by Exscientia's Centaur ChemistTM platform are highly opitimised to satisfy the multiple pharmacology criteria required to enter a compound into the clinic and to achieve these goals in a revolutionary time scale. Centaur Chemist transforms drug discovery into a formalized set of moves whilst also allowing the system to learn strategy from human experts.
Exscientia statement ends
| || |
T: 020 7332 2338
Company website: www.frontierip.co.uk
M: 07464 546 025
| || |
T: 0203 328 5656
| || |
| || |
+44(0) 78 9685 9386
NOTES FOR EDITORS
Exscientia is a global Artificial Intelligence (AI)-driven drug discovery company and the first to have novel chemical molecules assessed in a clinical setting. Fusing the power of the original AI-design with the experience of seasoned drug hunters, Exscientia's Centaur Chemist™ platform enables the discovery of exquisitely optimised molecules with breakthrough productivity.
In tandem, Exscientia's Centaur Biologist™ platform drives the flexible analysis and prioritisation of discovery targets across all pharmaceutically relevant disease space. For more information visit us on www.exscientia.ai or follow us on Twitter @exscientialtd.
SRI Biosciences has produced several marketed drugs and advanced more than 100 drugs to clinical trials. The division is focused on novel platforms and programs in a variety of therapeutic areas targeting high unmet medical needs. SRI Biosciences collaborates with a broad range of partners from small and virtual biotechnology companies to top 10 pharmaceutical companies and other leading industry partners. More information is available at www.sri.com.
The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.
ABOUT RNS REACH ANNOUNCEMENTS
This is an RNS Reach announcement. RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.
This information is provided by RNS, the news service of the
Quick facts: Frontier IP Group PLC
Market Cap: £30.66 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE